Searched for
BIOPHARMACEUTICALS
Cipla sets sights on first-wave gains from rollout of Keytruda BiosimilarCipla has partnered with Qilu Pharmaceutical to commercialize a biosimilar of Keytruda, which is a major cancer treatment. The patent for t...- China won’t stop its AI from going global, but it wants control over how it travelsProposed rules from China have raised concerns that it could make it harder for its AI companies to take their models overseas, at a time w...
- AstraZeneca strikes $40 million AI drug discovery deal with insitroAstraZeneca has entered a collaboration with insitro to explore new treatment options for challenging liver and heart diseases. The partner...
- AstraZeneca strikes $40 million AI drug discovery deal with insitroAstraZeneca has entered into a partnership with insitro to identify treatments for challenging liver and heart diseases. This collaboration...
- Biocon settles US patent dispute with Roche's Genentech, eyes 2027 Perjeta biosimilar launchBiocon announced a settlement with Genentech over its biosimilar, Pebrilzo, of the cancer drug Perjeta. The agreement allows Biocon to laun...
- Biocon clears path for cancer drug launchBiocon has finalized a global settlement and license agreement with Genentech for its drug Pebrilzo. This agreement addresses all ongoing l...
- Zydus moves closer to US market for Keytruda biosimilar as FDA accepts applicationZydus Lifesciences has received acceptance for its application regarding the biosimilar of Keytruda, which is a major cancer drug. The USFD...
- Existential threats join bubble fears as AI mood sobers at Singapore forumsDuring conferences in Singapore, significant apprehensions regarding the dangers of artificial intelligence emerged among investors and pol...
- When nothing is cheap, winners may come from any corner: 19 stocks with downside to upside potential of -28% to plus 22%Because each pharma company took a different road, they no longer rise and fall together. Where any one of them stands in 10 years depends ...
- Global Market: Hong Kong stocks rise as pharma, tech shares lead gainsHong Kong stocks gained on Tuesday, led by pharmaceutical and technology shares, with the Hang Seng rising 0.78% and Hang Seng Tech Index a...
- Indian companies must invest in R&D, move from generics to innovation-led industry: Pharma leadersIndian pharmaceutical leaders emphasize the need for investment in innovation to transition from generics to innovative products. They high...
- ET Business Excellence & Leadership Summit 2026: Celebrating visionaries redefining growth & leadershipThe ET Business Excellence & Leadership Summit 2026 brought together leaders to discuss brand development, innovation, and sustainability. ...
- Kiran Mazumdar-Shaw has a career lesson from 3 Nobel prize winners as AI forces layoffs and changes jobs across the worldBiocon chairperson Kiran Mazumdar-Shaw shared a message on persistence from three 2023 Nobel Prize winners as AI reshapes jobs and companie...
- Ichor Biologics seeks $80-100 million PE funding for minority stake saleIchor Biologics is seeking eighty to one hundred million dollars from private equity investors. The Hyderabad-based company operates in the...
- 5 stocks with consistent score improvement and upside potential of up to 22% in 1 year, according to analystsGiven the current situation both globally and domestically, one can expect more headwinds in the market. There is, on the domestic front, a...
- QDENGA dengue vaccine to hit India market in 2027; Dr Reddy’s to sell itIndia's first approved dengue vaccine, QDENGA, will launch in the private market by mid-2027. Dr Reddy's Laboratories will distribute and p...
- MSD inaugurates 2.5 lakh sq ft tech centre in HyderabadGlobal biopharmaceutical company MSD has opened a new technology centre in Hyderabad. This facility will enhance the company's digital, dat...
- Biocon shares rise 3% after Rs 638-crore block deal; Active Pine likely sellerBiocon shares rose after a block deal involving around 1.65 crore shares. Investor Active Pine was reportedly looking to sell up to 1.66 cr...
- Biocon shares rise 2% on 10-year Pertuzumab supply deal for breast cancer therapy in BrazilBiocon shares rose after the company secured a 10-year Pertuzumab supply contract in Brazil. The consortium with Bahiafarma and Bionovis re...
- Biocon signs 10-year Brazil supply deal for Pertuzumab breast cancer drugIn a significant move, Biocon has secured a ten-year contract in Brazil for the distribution of Pertuzumab, made possible through its colla...
Load More
